Accordingly, research is needed to determine whether fluvoxamine’s Sig-1R activation can reduce ER stress-related damage and improve cognitive and social deficits in schizophrenia, potentially offering new treatments for resistant and negative symptoms. This evidence concerns the gene SIGMAR1 and schizophrenia.